| Literature DB >> 33125399 |
Alberto Montero-Ruiz1,2, Laura A Fuentes1, Estela Pérez Ruiz1,3, Nuria García-Agua Soler1, Francisca Rius-Diaz4, Pilar Caro Aguilera1,3, Javier Pérez Frías1,3, Elisa Martín-Montañez1.
Abstract
Airway clearance therapy (ACT) is considered an important approach to improve airway clearance in children with cystic fibrosis (CF). Daily ACT administration requires substantial commitments of time and energy that complicate ACT and reduce its benefits. It is crucial to establish ACT as a positive routine. Music therapy (MT) is an aspect of integrative strategies to ameliorate the psycho-emotional consequences of chronic diseases, and a MT intervention could help children with CF between the ages of 2 and 17 develop a positive response. The aim of this randomized controlled trial was to evaluate the effects of specifically composed and recorded instrumental music as an adjunct to ACT. We compared the use of specifically composed music (Treated Group, TG), music that the patient liked (Placebo Group, PG), and no music (Control Group, CG) during the usual ACT routine in children with CF aged from 2 to 17. The primary outcomes, i.e., enjoyment and perception of time, were evaluated via validated questionnaires. The secondary outcome, i.e., efficiency, was evaluated in terms of avoided healthcare resources. Enjoyment increased after the use of the specifically composed music (children +0.9 units/parents +1.7 units; p<0.05) compared to enjoyment with no music (0 units) and familiar music (+0.5 units). Perception of time was 11.1 min (±3.9) less than the actual time in the TG (p<0.05), 3.9 min (±4.2) more than the actual time in the PG and unchanged in the CG. The potential cost saving related to respiratory exacerbations was €6,704.87, while the cost increased to €33,524.35 in the CG and to €13,409.74 in the PG. In conclusion, the specifically composed, played and compiled instrumental recorded music is an effective adjunct to ACT to establish a positive response and is an efficient option in terms of avoided costs. Trial registered as ISRCTN11161411. ISRCTN registry (www.isrctn.com).Entities:
Mesh:
Year: 2020 PMID: 33125399 PMCID: PMC7598495 DOI: 10.1371/journal.pone.0241334
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical trial inclusion and exclusion criteria.
| Participants diagnosed with CF based on international criteria [ | |
| Participants undergoing periodic clinic visits in the CF unit | |
| Participants in the target age range | |
| Participants with an understanding of the purpose of the study | |
| Participants without ACT prescription | |
| Participants with severe hearing loss | |
| Participants with clinical complications such that the ACT may have to be adapted or may be contraindicated: radiologic or clinical risk of pneumothorax or pneumomediastinum; barotrauma in the month prior to entry in the study; or past history of massive or life-threatening hemoptysis [ | |
| Transplant recipients or patients awaiting a lung transplant |
Abbreviations: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; ACT, airway clearance therapy.
Information about the clinical variables (age of diagnosis, body mass index, Bhalla score and respiratory infection exacerbations) was obtained from the clinical center.
Fig 1Flow diagram of the clinical trial.
Demographic and clinical data and baseline ACT variables.
| Parameters | Control Group (n = 15) | Placebo Group (n = 13) | Treated Group (n = 15) |
|---|---|---|---|
| 7.2 ± 4.3 (2–16) | 8.1 ± 5.6 (2–17) | 7.9 ± 4.7 (2–17) | |
| 6.8 ± 8.4 (0.5–24) | 6.8 ± 6.8 (1–24) | 6.4 ± 7 (0.5–24) | |
| 8 (53.3) | 9 (69.2) | 10 (66.7) | |
| 16.6 ± 1.7 (13.7–19.4) | 16.3 ± 2.2 (12.1–19.1) | 16.9 ± 2.2 (12.8–19.6) | |
| 19.4 ± 3.8 (13–25) | 18 ± 5 (10–25) | 18.9 ± 4.7 (9–24) | |
| 1.3 ± 0.5 (1–2) | 1.4 ± 0.5 (1–2) | 1.4 ± 0.5 (1–2) | |
| 26 ± 3.4 (10–60) | 22.4 ± 3.7 (10–45) | 27.3 ± 3.4 (10–60) |
Continuous variables are expressed as the mean ± SD (range). Categorical data are expressed as n (%).
1 Median ± SD (range): Kruskal-Wallis test was performed to compare groups.
2 N (%): Chi square test was performed to compare groups for the variable 'gender'.
3 Median ± SD (range): ANOVA test was performed to compare groups. No statistically significant differences were identified.
Abbreviations: BMI, body mass index; ACT, airway clearance therapy. Bhalla score: a lung damage severity rating system for high-resolution computed tomography in cystic fibrosis. The lower the Bhalla score is, the more severe the condition [22].
Fig 2Change in children’s and parents’ enjoyment.
(A) Children's and (B) parents' enjoyment. Enjoyment was assessed on 7-point Likert-type scales, where—3 was the least enjoyment, + 3 was the most enjoyment, and 0 was neutral. Values were measured at baseline and in the final interviews. The data are presented as the mean (± SD). Wilcoxon test was performed to compare the differences between the baseline and final measures in each group. Changes in children’s enjoyment: *p = 0.004 (Treated Group); &p = 0.035 (Placebo Group); p = 0.89 (Control Group). Changes in parents’ enjoyment: *p = 0.009 (Treated Group); p = 0.096 (Placebo Group); p = 0.492 (Control Group).
Fig 3Change in perception of time.
To analyze the perception of time, the apparent time value reported on the questionnaire was subtracted from the actual time value given (actual time—apparent time = perception of time). Positive value: perception of ACT shorter. Negative value: perception of ACT longer. Values above 0: participants felt they spent less time taking the ACT routine than the actual time they spent to taking it. Values below 0: participants felt they spent more time taking the ACT routine than the actual time they spent taking it. Differences were calculated at baseline and the final interviews. The data are presented as the mean (± SD). Wilcoxon test was performed to compare the differences between the baseline and final measures in each group. Changes: *p = 0.003 (Treated Group); p = 0.076 (Placebo Group); p = 0.857 (Control Group).
Healthcare resources in children with cystic fibrosis according to the different groups.
| Groups | Preintervention | During the intervention | Change | |||
|---|---|---|---|---|---|---|
| Exacerbations (n) | Related cost (€) | Exacerbations (n) | Related cost (€) | Exacerbations (n) | Related cost (€) | |
| 2 | 13,409.74 | 1 | 6,704.87 | -1 | -6,704.87 | |
| 1 | 6,704.87 | 3 | 20,114.61 | +2 | +13,409.74 | |
| 1 | 6,704.87 | 6 | 40,229.22 | +5 | +33,524.35 | |
Preintervention: 3-month period before the intervention; intervention: 3-month trial period; exacerbation: number of respiratory infection exacerbations that required hospitalization. Hospitalization cost (€) was estimated based on the associated diagnosis-related groups.